10:34 AM EDT, 03/27/2024 (MT Newswires) -- Altimmune's ( ALT ) shares were down about 5% in recent Wednesday trading after reporting a Q4 net loss of $0.54 per diluted share, wider than its net loss of $0.43 per diluted share a year earlier.

Analysts polled by Capital IQ expected a net loss of $0.38.

Revenue during the three months ended Dec. 31 was $37,000.

Analysts surveyed by Capital IQ expected no revenue.

The company finished 2023 with $198 million in cash, cash equivalents and short-term investments.

In its earnings announcement, the company reported phase 2 testing for its pemvidutide anti-obesity drug candidate demonstrated results comparable to the historic effects associated with diet and exercise, but said it was ending work on its HepTcell prospective treatment for hepatitis B. Altimmune ( ALT ) booked a $12.4 million impairment loss on intangible asset against its Q4 results after ending the program.

Price: 8.30, Change: -0.35, Percent Change: -4.05